Copyright Reports & Markets. All rights reserved.

Global Oligonucleotide Therapeutics Drug Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Oligonucleotide Therapeutics Drug by Type
    • 1.3.1 Overview: Global Oligonucleotide Therapeutics Drug Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Oligonucleotide Therapeutics Drug Consumption Value Market Share by Type in 2025
    • 1.3.3 Antisense Oligonucleotide
    • 1.3.4 Aptamer
    • 1.3.5 Other
  • 1.4 Global Oligonucleotide Therapeutics Drug Market by Application
    • 1.4.1 Overview: Global Oligonucleotide Therapeutics Drug Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Neuromuscular Diseases
    • 1.4.3 ATTR
    • 1.4.4 Hepatic VOD
    • 1.4.5 Other
  • 1.5 Global Oligonucleotide Therapeutics Drug Market Size & Forecast
  • 1.6 Global Oligonucleotide Therapeutics Drug Market Size and Forecast by Region
    • 1.6.1 Global Oligonucleotide Therapeutics Drug Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Oligonucleotide Therapeutics Drug Market Size by Region, (2021-2032)
    • 1.6.3 North America Oligonucleotide Therapeutics Drug Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Oligonucleotide Therapeutics Drug Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Oligonucleotide Therapeutics Drug Market Size and Prospect (2021-2032)
    • 1.6.6 South America Oligonucleotide Therapeutics Drug Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Oligonucleotide Therapeutics Drug Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Biogen
    • 2.1.1 Biogen Details
    • 2.1.2 Biogen Major Business
    • 2.1.3 Biogen Oligonucleotide Therapeutics Drug Product and Solutions
    • 2.1.4 Biogen Oligonucleotide Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Biogen Recent Developments and Future Plans
  • 2.2 Sarepta Therapeutics
    • 2.2.1 Sarepta Therapeutics Details
    • 2.2.2 Sarepta Therapeutics Major Business
    • 2.2.3 Sarepta Therapeutics Oligonucleotide Therapeutics Drug Product and Solutions
    • 2.2.4 Sarepta Therapeutics Oligonucleotide Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Sarepta Therapeutics Recent Developments and Future Plans
  • 2.3 Jazz Pharmaceuticals
    • 2.3.1 Jazz Pharmaceuticals Details
    • 2.3.2 Jazz Pharmaceuticals Major Business
    • 2.3.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Drug Product and Solutions
    • 2.3.4 Jazz Pharmaceuticals Oligonucleotide Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Jazz Pharmaceuticals Recent Developments and Future Plans
  • 2.4 Bausch & Lomb
    • 2.4.1 Bausch & Lomb Details
    • 2.4.2 Bausch & Lomb Major Business
    • 2.4.3 Bausch & Lomb Oligonucleotide Therapeutics Drug Product and Solutions
    • 2.4.4 Bausch & Lomb Oligonucleotide Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Bausch & Lomb Recent Developments and Future Plans
  • 2.5 Alnylam Pharmaceuticals
    • 2.5.1 Alnylam Pharmaceuticals Details
    • 2.5.2 Alnylam Pharmaceuticals Major Business
    • 2.5.3 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Drug Product and Solutions
    • 2.5.4 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
  • 2.6 Dynavax Technologies
    • 2.6.1 Dynavax Technologies Details
    • 2.6.2 Dynavax Technologies Major Business
    • 2.6.3 Dynavax Technologies Oligonucleotide Therapeutics Drug Product and Solutions
    • 2.6.4 Dynavax Technologies Oligonucleotide Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Dynavax Technologies Recent Developments and Future Plans
  • 2.7 Kastle therapeutics
    • 2.7.1 Kastle therapeutics Details
    • 2.7.2 Kastle therapeutics Major Business
    • 2.7.3 Kastle therapeutics Oligonucleotide Therapeutics Drug Product and Solutions
    • 2.7.4 Kastle therapeutics Oligonucleotide Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Kastle therapeutics Recent Developments and Future Plans
  • 2.8 Akcea Therapeutics
    • 2.8.1 Akcea Therapeutics Details
    • 2.8.2 Akcea Therapeutics Major Business
    • 2.8.3 Akcea Therapeutics Oligonucleotide Therapeutics Drug Product and Solutions
    • 2.8.4 Akcea Therapeutics Oligonucleotide Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Akcea Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Oligonucleotide Therapeutics Drug Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Oligonucleotide Therapeutics Drug by Company Revenue
    • 3.2.2 Top 3 Oligonucleotide Therapeutics Drug Players Market Share in 2025
    • 3.2.3 Top 6 Oligonucleotide Therapeutics Drug Players Market Share in 2025
  • 3.3 Oligonucleotide Therapeutics Drug Market: Overall Company Footprint Analysis
    • 3.3.1 Oligonucleotide Therapeutics Drug Market: Region Footprint
    • 3.3.2 Oligonucleotide Therapeutics Drug Market: Company Product Type Footprint
    • 3.3.3 Oligonucleotide Therapeutics Drug Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Oligonucleotide Therapeutics Drug Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Oligonucleotide Therapeutics Drug Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Oligonucleotide Therapeutics Drug Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Oligonucleotide Therapeutics Drug Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Oligonucleotide Therapeutics Drug Consumption Value by Type (2021-2032)
  • 6.2 North America Oligonucleotide Therapeutics Drug Market Size by Application (2021-2032)
  • 6.3 North America Oligonucleotide Therapeutics Drug Market Size by Country
    • 6.3.1 North America Oligonucleotide Therapeutics Drug Consumption Value by Country (2021-2032)
    • 6.3.2 United States Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Oligonucleotide Therapeutics Drug Consumption Value by Type (2021-2032)
  • 7.2 Europe Oligonucleotide Therapeutics Drug Consumption Value by Application (2021-2032)
  • 7.3 Europe Oligonucleotide Therapeutics Drug Market Size by Country
    • 7.3.1 Europe Oligonucleotide Therapeutics Drug Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)
    • 7.3.3 France Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Oligonucleotide Therapeutics Drug Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Oligonucleotide Therapeutics Drug Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Oligonucleotide Therapeutics Drug Market Size by Region
    • 8.3.1 Asia-Pacific Oligonucleotide Therapeutics Drug Consumption Value by Region (2021-2032)
    • 8.3.2 China Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)
    • 8.3.5 India Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Oligonucleotide Therapeutics Drug Consumption Value by Type (2021-2032)
  • 9.2 South America Oligonucleotide Therapeutics Drug Consumption Value by Application (2021-2032)
  • 9.3 South America Oligonucleotide Therapeutics Drug Market Size by Country
    • 9.3.1 South America Oligonucleotide Therapeutics Drug Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Oligonucleotide Therapeutics Drug Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Oligonucleotide Therapeutics Drug Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Oligonucleotide Therapeutics Drug Market Size by Country
    • 10.3.1 Middle East & Africa Oligonucleotide Therapeutics Drug Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Oligonucleotide Therapeutics Drug Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Oligonucleotide Therapeutics Drug Market Drivers
  • 11.2 Oligonucleotide Therapeutics Drug Market Restraints
  • 11.3 Oligonucleotide Therapeutics Drug Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Oligonucleotide Therapeutics Drug Industry Chain
  • 12.2 Oligonucleotide Therapeutics Drug Upstream Analysis
  • 12.3 Oligonucleotide Therapeutics Drug Midstream Analysis
  • 12.4 Oligonucleotide Therapeutics Drug Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Oligonucleotide Therapeutics Drug market size was valued at US$ 402 million in 2025 and is forecast to a readjusted size of US$ 597 million by 2032 with a CAGR of 5.9% during review period.
    Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global Oligonucleotide Therapeutics Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Oligonucleotide Therapeutics Drug market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Oligonucleotide Therapeutics Drug market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Oligonucleotide Therapeutics Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Oligonucleotide Therapeutics Drug market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Oligonucleotide Therapeutics Drug
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Oligonucleotide Therapeutics Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics, Akcea Therapeutics, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Oligonucleotide Therapeutics Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Antisense Oligonucleotide
    Aptamer
    Other
    Market segment by Application
    Neuromuscular Diseases
    ATTR
    Hepatic VOD
    Other
    Market segment by players, this report covers
    Biogen
    Sarepta Therapeutics
    Jazz Pharmaceuticals
    Bausch & Lomb
    Alnylam Pharmaceuticals
    Dynavax Technologies
    Kastle therapeutics
    Akcea Therapeutics
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Oligonucleotide Therapeutics Drug product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Oligonucleotide Therapeutics Drug, with revenue, gross margin, and global market share of Oligonucleotide Therapeutics Drug from 2021 to 2026.
    Chapter 3, the Oligonucleotide Therapeutics Drug competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Oligonucleotide Therapeutics Drug market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Oligonucleotide Therapeutics Drug.
    Chapter 13, to describe Oligonucleotide Therapeutics Drug research findings and conclusion.

    Buy now